Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-09Clinical Trial Update: Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease [Phase 2]
A Phase 2 clinical trial is evaluating the combination of orelabrutinib, lisaftoclax, and rituximab in untreated, high-risk Mantle Cell Lymp…
-
CLINICAL_TRIALS trial_result · 2025-12-09Clinical Trial Update: Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) [NA]
Clinical trial update on adaptive bridging radiotherapy for relapsed/refractory B-cell lymphomas prior to CAR-T therapy; the study status is…
-
CLINICAL_TRIALS trial_result · 2025-12-08Clinical Trial Update: Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL [Phase 2]
Phase 2 trial assessing rituximab, bendamustine, and cytarabine followed by venetoclax in high-risk elderly patients with mantle cell lympho…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study
A single-center cohort study is assessing biomarkers of cardiovascular complications in patients treated with second-generation BTK inhibito…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial [Phase 4]
Phase 4 multi-center prospective trial evaluating ZSDT for relapsed/refractory mantle cell lymphoma after BTK inhibitor failure; the study i…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 clinical trial update on Pemigatinib in relapsed or refractory B-cell non-Hodgkin lymphomas, including mantle cell lymphoma and marg…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating obinutuzumab, zanubrutinib, and lenalidomide as first-line treatment for mantle cell lymphoma, with t…
-
CLINICAL_TRIALS trial_result · 2025-12-02Clinical Trial Update: Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma [Phase 1, Phase 2]
Clinical trial update describing a multicenter, single-arm Phase I/II exploratory study to assess the safety and efficacy of a fully human B…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma [NA]
This clinical trial update reports an ongoing study evaluating a three-drug regimen (pomalidomide plus orelabrutinib and zuberitamab) in unt…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma [Phase 1]
This clinical trial update describes a Phase 1 study of pevonedistat in combination with ibrutinib for relapsed or refractory chronic lympho…
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial examined lenalidomide combined with blinatumomab for relapsed non-Hodgkin lymphoma across multiple subtypes and has compl…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination of modified CD19 CAR T cells with acalabrutinib for relapsed or refractory mantle cel…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) [Phase 2]
Phase 2 study evaluating ICP-248 for efficacy and safety in relapsed or refractory mantle cell lymphoma, currently recruiting (APEX-06).
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial update evaluating ibrutinib in combination with rituximab and consolidation chemotherapy for young patients with newl…
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) [Phase 2]
Phase 2 trial update for Brexucabtagene Autoleucel (KTE-X19) in relapsed/refractory mantle cell lymphoma (Cohort 3) indicates the study stat…
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating CTX112 in relapsed or refractory B-cell malignancies is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: A Disease Registry of Patients With Mantle Cell Lymphoma
This is a disease registry study collecting data on patients with Mantle Cell Lymphoma, sponsored by AstraZeneca. The study status is COMPLE…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination of acalabrutinib and rituximab for previously untreated mantle cell lymphoma and is c…
-
CLINICAL_TRIALS trial_result · 2025-11-10Clinical Trial Update: Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine [Phase 1]
A Phase 1 clinical trial evaluating a haploidentical bone marrow transplant using post-transplant cyclophosphamide and bendamustine has comp…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1]
This document provides an update on a Phase 1 clinical trial evaluating the combination of lenalidomide and ibrutinib in patients with relap…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Long-term Follow-up Study of Patients Receiving CAR-T Cells
This clinical trial update outlines a long-term follow-up study of patients who received CAR-T cell therapy. Sponsored by the Medical Colleg…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) [Phase 1]
Phase 1 clinical trial evaluating the combination of Rituximab and Tafasitamab with allogeneic NK cells in relapsed/refractory B-cell non-Ho…
-
CLINICAL_TRIALS trial_result · 2025-11-03Clinical Trial Update: Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating nivolumab in patients with hematologic malignancies after CAR-T therapy; results have been posted with the study cu…
-
FDA approval · 2025-10-21FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
CLINICAL_TRIALS trial_result · 2025-10-21Clinical Trial Update: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma [Phase 2]
A Phase 2 trial is evaluating the combination of acalabrutinib, venetoclax, and rituximab in treatment-naïve mantle cell lymphoma; the study…